Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Reaches New 12-Month Low – Time to Sell?

Posted by Teresa Graham on Oct 30th, 2024

Bayer Aktiengesellschaft (OTCMKTS:BAYRY – Get Free Report) hit a new 52-week low during trading on Wednesday . The stock traded as low as $6.76 and last traded at $6.81, with a volume of 1225637 shares traded. The stock had previously closed at $6.95.

Analyst Upgrades and Downgrades

Separately, Bank of America upgraded Bayer Aktiengesellschaft from an “underperform” rating to a “neutral” rating in a research report on Friday, September 6th. One equities research analyst has rated the stock with a sell rating and eight have given a hold rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Hold”.

Read Our Latest Report on BAYRY

Bayer Aktiengesellschaft Trading Down 2.0 %

The firm has a market capitalization of $26.76 billion, a P/E ratio of -7.99 and a beta of 1.08. The company has a quick ratio of 0.86, a current ratio of 1.27 and a debt-to-equity ratio of 1.04. The business has a 50-day moving average price of $7.68 and a 200-day moving average price of $7.48.

Bayer Aktiengesellschaft (OTCMKTS:BAYRY – Get Free Report) last released its quarterly earnings data on Tuesday, August 6th. The company reported $0.25 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.25. Bayer Aktiengesellschaft had a positive return on equity of 16.96% and a negative net margin of 2.74%. The business had revenue of $12 billion for the quarter. Analysts anticipate that Bayer Aktiengesellschaft will post 1.38 earnings per share for the current year.

About Bayer Aktiengesellschaft

(Get Free Report)

Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women’s health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and digital solutions, and contrast agents, as well as cell and gene therapy.